Program
seralutinib
Also written as “Seralutinib”, “GB002 (seralutinib)” and “GB002”.
Its studies are mostly in Pulmonary Arterial Hypertension · Hypertension, Pulmonary, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GB002, Inc., a wholly owned subsidiary of Gossamer Bio | 30 open or running | phase 2since Jun 30, 2020 | Mar 8, 2018 | none ahead |
| GB002 | 20 open or running | phase 3since Jun 28, 2023 | Jun 28, 2023 | none ahead |
| Gossamer Bio USA | 21 open or running | phase 3since Jan 19, 2024 | Mar 23, 2021 | Dec 2026phase 3 · NCT06274801 |
| Zhejiang Echon Biopharm | 11 open or running | phase 1since Apr 30, 2024 | Apr 30, 2024 | none ahead |
Also a collaborator on its studies: Chiesi Farmaceutici and Pulmokine.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 8, 2018First study: phase 1 study in Safety IssuesNew to GB002, Inc., a wholly owned subsidiary of Gossamer BioGB002, Inc., a wholly owned subsidiary of Gossamer Bio · NCT03473236 · 66 enrolled · United States
- Apr 22, 2019Phase 1 study in Pulmonary Arterial HypertensionGB002, Inc., a wholly owned subsidiary of Gossamer Bio · NCT03926793 · 8 enrolled · United States, United Kingdom
- Jun 30, 2020Phase 2 study in Familial Primary Pulmonary HypertensionGB002, Inc., a wholly owned subsidiary of Gossamer Bio · NCT04456998 · 86 enrolled · United States, Australia, Austria and more
- Mar 23, 2021Gossamer Bio USA’s first study: phase 2 study in Pulmonary Arterial HypertensionNew to Gossamer Bio USAGossamer Bio USA · NCT04816604 · 74 enrolled · United States, Australia, Czechia and more
- Jun 28, 2023GB002’s first study: phase 3 study in Pulmonary Arterial HypertensionNew to GB002GB002 · NCT05934526 · 390 enrolled · United States, Argentina, Australia and more
- Jan 19, 2024Phase 3 study in Pulmonary Arterial HypertensionGossamer Bio USA · NCT06274801 · 330 planned · United States, Argentina, Australia and more
- Apr 30, 2024Zhejiang Echon Biopharm’s first study: phase 1 study in HealthyNew to Zhejiang Echon BiopharmZhejiang Echon Biopharm · NCT06423261 · 100 enrolled · China
- Sep 12, 2025Phase 3 study in Hypertension, PulmonaryGB002 · NCT07181382 · 480 enrolled · United States, Israel
Ahead
- Dec 2026Primary completion: phase 3 study in Pulmonary Arterial HypertensionGossamer Bio USA · NCT06274801
TargetBeta
“Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor; Macrophage colony stimulating factor receptor inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| quizartinibrule | Daiichi Sankyo | phase 3 | 22 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07181382Hypertension, Pulmonary · United States, Israel | 3 | Suspended | GB002 | Dec 2028 | 480 |
| NCT06423261Healthy · China | 1 | Active, not recruiting | Zhejiang Echon Biopharm | Dec 30, 2025 | 100 |
| NCT06274801Pulmonary Arterial Hypertension · United States, Argentina, Australia and more | 3 | Recruiting | Gossamer Bio USA | Dec 2026 | 330 |
| NCT05934526Pulmonary Arterial Hypertension · United States, Argentina, Australia and more | 3 | Completed | GB002 | Nov 27, 2025 | 390 |
| NCT04816604Pulmonary Arterial Hypertension · United States, Australia, Czechia and more | 2 | Terminated | Gossamer Bio USA | Sep 9, 2026 | 74 |
| NCT04456998Familial Primary Pulmonary Hypertension · United States, Australia, Austria and more | 2 | Completed | GB002, Inc., a wholly owned subsidiary of Gossamer Bio | Oct 17, 2022 | 86 |
| NCT03926793Pulmonary Arterial Hypertension · United States, United Kingdom | 1 | Completed | GB002, Inc., a wholly owned subsidiary of Gossamer Bio | May 5, 2021 | 8 |
| NCT03473236Safety Issues · United States | 1 | Completed | GB002, Inc., a wholly owned subsidiary of Gossamer Bio | Dec 3, 2018 | 66 |
How it is read
Names in the registry
- “Seralutinib”, 3 entries
- “GB002 (seralutinib)”, 2 entries
- “GB002”, 2 entries
- “GB002 Recombinant Peptide Inhalation Solution”, 1 entry
Conditions, from the studies’ own filings
- Pulmonary Arterial Hypertension, 4 studies
- Hypertension, Pulmonary, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.